Price T Rowe Associates Inc. MD Raises Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Price T Rowe Associates Inc. MD lifted its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 7.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,283,207 shares of the biotechnology company's stock after buying an additional 162,079 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 3.76% of Ascendis Pharma A/S worth $314,330,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Wilmington Savings Fund Society FSB bought a new position in shares of Ascendis Pharma A/S in the third quarter worth approximately $30,000. Jones Financial Companies Lllp increased its holdings in shares of Ascendis Pharma A/S by 394.0% in the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after buying an additional 197 shares during the last quarter. Blue Trust Inc. raised its position in shares of Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after buying an additional 328 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 214 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Ascendis Pharma A/S by 195.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock worth $138,000 after acquiring an additional 664 shares during the last quarter.

Analyst Ratings Changes

Several brokerages have issued reports on ASND. The Goldman Sachs Group lifted their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Cantor Fitzgerald upped their target price on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 25th. Morgan Stanley set a $180.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, February 18th. Royal Bank of Canada assumed coverage on shares of Ascendis Pharma A/S in a report on Wednesday, April 16th. They set an "outperform" rating and a $205.00 target price on the stock. Finally, UBS Group started coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a "buy" rating and a $196.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $204.67.

Ascendis Pharma A/S Price Performance

Ascendis Pharma A/S stock traded up $1.70 during midday trading on Tuesday, reaching $166.58. 276,857 shares of the company traded hands, compared to its average volume of 488,107. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $169.37. The firm has a market capitalization of $10.16 billion, a price-to-earnings ratio of -23.46 and a beta of 0.54. The business has a 50 day moving average of $153.97 and a two-hundred day moving average of $139.28.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, equities analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.